Hugel Q1 2026: Sales 116.6B, OP 47.6B, Net Cash 223.3B KRW
-
Q1 2026 consolidated sales 116.6B KRW, OP 47.6B (OPM 40.8%), net profit (controlling) 39.3B
-
Net cash 223.3B, debt ratio 9.6% (total borrowings 26B)
-
Treasury shares 1,500,741 (12.20%), no short-term buyback/cancellation plan
-
Botulinum toxin (Botulax) sales 55.4%, filler 27.6%, cosmetics 15.4%
-
Credit rating AA+ (up from AA0)
-
Ongoing Medytox ITC appeal, company expects limited impact
-
R&D 3.1B (2.67% of sales)
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: Hugel (145020)
-
Submission: Hugel, Inc.
-
Receipt: 05-15-2026